Morning Breakouts

Latest California Healthline Stories

Officials Link Source Of Oral Health Infection In 7 Kids To Anaheim Dental Office

One parent reports trouble getting a copy of his daughter’s medical records from the clinic in question, the Children’s Dental Group in Anaheim. In other news from around California, a Campbell doctor’s work with veterans and disabled patients is recognized, and the Ventura County chief medical examiner quits.

EpiPen-Maker’s CEO To Face Congressional Fire At Hearing On Price Gouging

Chief Executive Heather Bresch will testify in front of the House Oversight and Government Reform Committee next week. Meanwhile, senators will introduce a bill requiring drugmakers to give a 30-day notice and justification of any prescription drug price increase of more than 10 percent. And The Associated Press examines pharmaceutical discount cards.

Survey Of Employers Finds Modest Rise In 2015 Health Premiums, But Deductibles Soared

The Kaiser Family Foundation analysis finds that premiums for health insurance family plans offered through a workplace grew about 3 percent. Yet that was partly the result of employers shifting costs to workers through increased deductibles, which have grown nearly six times as fast as wages.

Clinton Reveals More Details On Pneumonia; Trump Talks Weight, Diet With Dr. Oz

The campaign’s spotlight has shifted toward the candidates’ health in recent days, but the underlying concern has more to do with transparency issues. In other election news, Donald Trump’s maternity-leave plan gets mixed reviews from U.S. lawmakers.

Patient Use Of Medical Marijuana Under Consideration At Marin General Hospital

The Marin Healthcare District Board will study the clinical and legal issues of allowing open drug use in the facility. In other hospital news, Santa Cruz County receives a $2.5-million award to build a dedicated mental health center.

Mylan Ranks No. 2 In Executive Pay Among Drug Companies, Far Outpacing Others Its Size

The top five managers took home almost $300 million over the past five years, The Wall Street Journal reports amid continuing questions about the manufacter’s EpiPen pricing. News outlets also report on an FDA warning to doctors about drug risks, the pros and cons of pharmaceutical ads and a drop in the cost of generics.